EU/3/19/2214

Table of contents

About

On 17 October 2019, orphan designation EU/3/19/2214 was granted by the European Commission to Voisin Consulting S.A.R.L., France, for nirogacestat for the treatment of soft tissue sarcoma.

Key facts

Active substance
Nirogacestat
Disease / condition
Treatment of soft tissue sarcoma
Date of first decision
17/10/2019
Outcome
Positive
EU designation number
EU/3/19/2214

Sponsor's contact details

Voisin Consulting S.A.R.L.
64 Avenue Pierre Grenier
92100 Boulogne Billancourt
France
Tel:  00 33 141 31 83 00
E-mail: orphan@voisinconsulting.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating